- Tytuł:
- Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Neurology December 2020 19(12):988-997
Czasopismo naukowe